Dan Mendelson serves as a Fellow of Advisory Strategy at Inovalon, a role created to recognize Mr. Mendelson for a distinguished career at Inovalon and Avalere. In this role, Mr. Mendelson mentors emerging leaders within the Company and supports key industry relationships, industry thought-leadership, and advisory strategy initiatives at Inovalon.
Prior to this role, Mr. Mendelson was the president of Avalere Health, a subsidiary of Inovalon focused on providing high-impact, data-driven strategic insights to leading organizations across the healthcare ecosystem. In this role, Mr. Mendelson was responsible for all aspects of Avalere’s business goals and commitments around day-to-day product and service delivery, performance, support, and client value achievement, expanding the Company’s industry leading capabilities in data-driven advisory services and business intelligence solutions within the pharmaceutical and life sciences industry.
Prior to founding Avalere Health, Mr. Mendelson served as associate director for Health at the Office of Management and Budget (OMB) in the Clinton White House from 1998 to 2000. He was responsible for the full healthcare portfolio including Medicare, Medicaid, the National Institutes of Health (NIH) Centers for Disease Control and Prevention (CDC) and the Federal Drug Administration (FDA). His work included development of the Medicare pharmaceutical benefit, Presidential initiatives in health information technology and medical error prevention, the electronic disease surveillance system, and federal policies in reimbursement and technology assessment.
Preceding his position at OMB, Mr. Mendelson was senior vice president of The Lewin Group and director of the Medical Technology Practice. During his eight-year tenure at Lewin he had a range of responsibilities, including management of a transnational pharmaceutical and medical device consulting practice. Between 1994 and 1996, Mr. Mendelson was also closely involved in the operations of Value Rx, a pharmacy benefit management company (PBM). He also actively assisted both Value Health and Quintiles Transnational in due diligence on acquisitions.
Mr. Mendelson is an operating partner at Welsh, Carson, Anderson and Stowe, and serves on the Board of Champions Oncology and Centrexion Corporation. He previously served on the boards of Coventry Healthcare (sold to Aetna in 2013), PharMerica Corporation (PMC) and HMS holdings (HMSY).
Mr. Mendelson has published widely in peer-reviewed and professional journals on health information technology, the costs of disease, hospital costs and operations, physician payment, the economics of managed care, medical malpractice and a range of other topics. He holds an undergraduate degree in economics and viola performance from Oberlin College, and a Masters degree in Public Policy from the Kennedy School of Government at Harvard University.